title: In vitro dissolution study of atorvastatin binary solid dispersion.
abstract: The aim of the present study was to improve the solubility and dissolution rate of atorvastatin (ATV), a slight water-soluble drug, by solid dispersion (SD) technique using a hydrophilic carrier Poloxamer 188 (POL188). Physical mixing (PM) and solvent evaporation (SE) method were used to prepare ATV-SD where different drug-carrier ratios were used. Prepared formulations were characterized in their solid state by solubility study; differential scanning calorimetry, scanning electron microscopy, and Fourier transform infrared spectroscopy which demonstrated changes in the formulations supporting the improved solubility. Percent content of POL188 in the SD matrix was found to play the pivotal role in the improvement of dissolution property of ATV. In case of PM, highest enhancement in drug release was found for 1:3 ratio (P < 0.05, ANOVA Single factor) whereas in case of SE, 3:0.5 ratio of ATV-POL188 resulted the maximum enhancement in ATV release (P < 0.05, ANOVA Single factor). Analysis of dissolution data of optimized formula indicated the best fitting with Peppas-Korsmeyer model and the drug release kinetics was fickian diffusion. In conclusion, binary SD prepared by both PM and SE technique using POL188 could be considered as a simple, efficient method to prepare ATV solid dispersions with significant improvement in the dissolution rate.
authors: Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh.
authors: Rahat
authors: R
authors: Jahan
authors: Md Saiful
authors: MS
authors: Islam
authors: Ahmad
authors: A
authors: Tanwir
authors: Jakir Ahmed
authors: JA
authors: Chowdhury
keywords: Atorvastatin; physical mixing; poloxamer 188; solid dispersion; solvent evaporation
references: Acta Pharm. 2009 Dec;59(4):453-61
references: 19919934
references: J Pharm Sci. 1971 Sep;60(9):1281-302
references: 4935981
references: Pharm Res. 1993 Oct;10(10):1461-5
references: 8272408
references: J Adv Pharm Technol Res. 2010 Apr;1(2):221-8
references: 22247849
references: J Pharm Pharmacol. 2010 Nov;62(11):1599-606
references: 21039544
references: J Adv Pharm Technol Res. 2010 Jul;1(3):326-9
references: 22247865
references: Clin Pharmacokinet. 2003;42(13):1141-60
references: 14531725
references: AAPS PharmSciTech. 2009;10(4):1206-15
references: 19862626
references: J Adv Pharm Technol Res. 2010 Apr;1(2):180-9
references: 22247844
references: J Pharm Sci. 2005 May;94(5):1079-89
references: 15793810
references: Int J Pharm. 2007 Oct 1;343(1-2):228-37
references: 17597315
references: J Pharm Sci. 2011 Aug;100(8):3316-3331
references: 21607951
references: Eur J Pharm Sci. 2000;10(4):311-22
references: 10838021
references: Drug Dev Ind Pharm. 2005 Jul;31(6):473-89
references: 16109621
references: Drug Dev Ind Pharm. 2000 Nov;26(11):1141-50
references: 11068687
references: Int J Pharm. 2013 Aug 30;453(1):253-84
references: 22820134
references: Clin Pharmacol Ther. 1996 Dec;60(6):687-95
references: 8988072
references: Int J Pharm. 2002 Dec 5;249(1-2):45-58
references: 12433433
references: Int J Pharm. 2003 Sep 16;263(1-2):105-11
references: 12954185
references: Drug Dev Ind Pharm. 2003 Oct;29(9):997-1004
references: 14606663
references: Int J Pharm. 2004 Nov 22;286(1-2):69-80
references: 15501003
references: Drug Dev Ind Pharm. 2005 Jan;31(1):1-10
references: 15704852